According to a disclosure dated 20 October 2025, Consun Pharmaceutical Group Limited (01681) confirmed that its total number of issued ordinary shares remained at 847,973,407 as of 20 October 2025, unchanged from the opening balance on 17 October 2025.

The announcement outlines recent share repurchase activities conducted between 14 October and 20 October 2025. On 20 October 2025, 100,000 shares were repurchased on the Hong Kong Stock Exchange within a price range of HKD 15.39 to HKD 15.47 per share, amounting to HKD 1,541,320 in total. Overall, 6,232,000 shares have been repurchased under the existing mandate dated 22 May 2025, representing approximately 7.3209% of the company’s issued shares at the time the mandate was granted. A moratorium on any new share issuance or sale of treasury shares lasts until 19 November 2025 following the repurchases.

The company confirms that all repurchases were conducted in accordance with relevant regulations and that, despite these on-market repurchases, the issued share count stands at 847,973,407 as of 20 October 2025.